Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on March 7, 2025, covering an event that occurred on March 4, 2025. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol "SILO".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes
On March 4, 2025, the United States Patent and Trademark Office granted Patent No. US 12,239,614 to Silo Pharma, Inc. The patent, titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females," was exclusively licensed to the company from Columbia University based on Patent Application Serial No. 17/954864.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items beyond the patent grant.
Investor Verification Checklist
- Verify the scope and commercial potential of Patent No. US 12,239,614 regarding stress-induced affective disorders in females.
- Confirm the terms of the exclusive license agreement with Columbia University.
- Review the company's pipeline status to understand how this patent integrates with current development programs.